Dok Hyun Yoon

A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis

Seok Jin Kim, Dok Hyun Yoon, Arnaud Jaccard et al. · The Lancet Oncology · 2016 · 386 citations · Full text

Medicine, Clinical Sciences, Oncology +15

ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma

Grzegorz S. Nowakowski, Annalisa Chiappella, Randy D. Gascoyne et al. · Journal of Clinical Oncology · 2021 · 270 citations · Full text

Medicine, Hematology, Oncology +15

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

Meletios Α. Dimopoulos, Francesca Gay, Fredrik Schjesvold et al. · The Lancet · 2018 · 236 citations · Full text

Medicine, Hematology, Pharmacotherapy +15

Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis

Jeong-Eun Kim, Yunsuk Choi, Dok Hyun Yoon et al. · Lung Cancer · 2009 · 218 citations

Medicine, Oncology, Pharmacology +14

Pyridoxine Is Not Effective to Prevent Hand-Foot Syndrome Associated With Capecitabine Therapy: Results of a Randomized, Double-Blind, Placebo-Controlled Study

Yoon‐Koo Kang, Sung Sook Lee, Dok Hyun Yoon et al. · Journal of Clinical Oncology · 2010 · 129 citations · Full text

Medicine, Oncology, Pharmacology +16